Independent Prognostic Value of BRAF V600E for Recurrence in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis
Cancers · 17.07.2026 · 18 (14) · 2299
DOI: 10.3390/cancers18142299 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.07.2026. Verfasst von Sandeep Kumar Parvathareddy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The independent prognostic value of BRAF V600E in papillary thyroid carcinoma (PTC) remains uncertain. Current risk stratification schemes incorporate BRAF inconsistently, reflecting uncertainty about its independent association with recurrence. A systematic review and meta-analysis were conducted to evaluate the association between BRAF V600E and recurrence-related outcomes in PTC.
Methods
PubMed and Embase were searched for observational cohort studies reporting recurrence, recurrence-free survival, or disease-free survival according to BRAF status and providing multivariate-adjusted hazard ratios (HRs). Primary analysis included studies in which multivariate models adjusted for tumor size or American Joint Committee on Cancer (AJCC) tumor (T) category, whereas sensitivity analysis included all eligible multivariate studies irrespective of tumor size adjustment. Random-effects models were used to pool HRs with 95% confidence intervals (CIs), and heterogeneity was quantified with I2. Thirty-five cohort studies (n = 14,982 patients) met the inclusion criteria.
Results
In the primary analysis of 27 studies adjusting for tumor size or T category, BRAF V600E was associated with a 58% higher risk of recurrence (pooled HR 1.58, 95% CI 1.25–1.99; I2 = 56.2%). In the sensitivity analysis, results remained consistent (pooled HR 1.40, 95% CI 1.11–1.76; I2 = 64.5%). The funnel plot and Egger’s regression test did not indicate substantial publication bias.
Conclusions
Overall, BRAF V600E was associated with a modest but statistically significant increase in recurrence risk in PTC after adjustment for tumor size or T category. However, given the heterogeneity of included studies and variability in multivariable adjustment, these findings should be interpreted as supporting BRAF V600E as a complementary rather than a standalone prognostic marker.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Human Cancer Genomic Research, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
- Department of Surgery, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
- Department of Pathology, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
ORCID-Profile: Saud Azam, Khawla S Al-Kuraya
Zitieren
APA
Parvathareddy, S. K., Qadri, Z., Al-Rasheed, M., Azam, S., Siraj, N., Al-Sobhi, S. S., Al-Dayel, F., & Al-Kuraya, K. S. (2026). Independent Prognostic Value of BRAF V600E for Recurrence in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Cancers, 18(14), 2299. https://doi.org/10.3390/cancers18142299
Vancouver
Parvathareddy SK, Qadri Z, Al-Rasheed M, Azam S, Siraj N, Al-Sobhi SS, et al. Independent Prognostic Value of BRAF V600E for Recurrence in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Cancers. 2026;18(14):2299. doi:10.3390/cancers18142299
BibTeX
@article{Parvathareddy2026,
author = {Parvathareddy, Sandeep Kumar and Qadri, Zeeshan and Al-Rasheed, Maha and Azam, Saud and Siraj, Nabil and Al-Sobhi, Saif S and Al-Dayel, Fouad and Al-Kuraya, Khawla S},
title = {Independent Prognostic Value of BRAF V600E for Recurrence in Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2299},
doi = {10.3390/cancers18142299}
}
EUVIMED